Lu Zaiming, Sun Wei, Wen Feng, Liang Hongyuan, Shan Ming, Guo Qiyong
Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China ; These authors contributed equally to this study.
Contemp Oncol (Pozn). 2013;17(2):176-83. doi: 10.5114/wo.2013.34622. Epub 2013 Apr 29.
This study aimed to evaluate the effect of percutaneous interventional treatment on obstructive jaundice caused by hepatocellular carcinoma with bile duct tumor thrombus.
A total of 16 patients with bile duct tumor thrombus were included in the current retrospective study. All the patients were subjected to percutaneous transhepatic biliary drainage (PTBD). Treatment included permanent external drainage, internal drainage and routine tube adjustment, and covered stents according to the patients' clinical manifestations.
The success rate of PTBD was 100%. Among all the patients, two were treated with permanent external drainage, seven were treated with internal drainage and routine tube adjustment, and seven were treated with detaining covered stents. All the drainage tubes were successfully pulled out from the patients receiving covered stents. Among all the 16 patients, the clinical symptoms and life quality of 12 patients (12/16, 75%) were improved. The average survival time of all the patients was 203.7 days (ranging from 30 days to 391 days) with the median survival time of 199.5 days.
Percutaneous interventional therapy for obstructive jaundice caused by hepatocellular carcinoma with bile duct tumor thrombus is a good choice. It improves patients' life quality. Permanent external drainage, internal drainage, and covered stents are alternative methods which should be chosen according to the patient's condition.
本研究旨在评估经皮介入治疗对肝细胞癌合并胆管癌栓所致梗阻性黄疸的疗效。
本回顾性研究共纳入16例胆管癌栓患者。所有患者均接受经皮肝穿刺胆道引流（PTBD）。根据患者临床表现，治疗包括永久性外引流、内引流及常规导管调整，以及置入覆膜支架。
PTBD成功率为100%。所有患者中，2例行永久性外引流，7例行内引流及常规导管调整，7例行留置覆膜支架。所有接受覆膜支架治疗的患者引流管均成功拔除。16例患者中，12例（12/16，75%）临床症状及生活质量得到改善。所有患者平均生存时间为203.7天（30天至391天），中位生存时间为199.5天。
经皮介入治疗肝细胞癌合并胆管癌栓所致梗阻性黄疸是一种不错的选择。它可改善患者生活质量。永久性外引流、内引流及覆膜支架是可供选择的方法，应根据患者病情选择。
